Complex immune correlates of protection in HIV-1 vaccine efficacy trials

A Recombinant Vesicular Stomatitis Virus Ebola Vaccine

(2017) Jason A. Regules et al.   NEW ENGLAND JOURNAL OF MEDICINE

Engineering broadly neutralizing antibodies for HIV prevention and therapy

(2016) Casey K. Hua et al.   ADVANCED DRUG DELIVERY REVIEWS

Adenovirus-based HIV-1 vaccine candidates tested in efficacy trials elicit CD8+ T cells with limited breadth of HIV-1 inhibition

(2016) Peter J. Hayes et al.   AIDS

Exploiting Mucosal Immunity for Antiviral Vaccines

(2016) Akiko Iwasaki   Annual Review of Immunology

Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency

(2016) Stylianos Bournazos et al.   CELL

HIV-Host Interactions: Implications for Vaccine Design

(2016) Barton F. Haynes et al.   Cell Host & Microbe

Towards HIV-1 remission: potential roles for broadly neutralizing antibodies

(2016) Ariel Halper-Stromberg et al.   JOURNAL OF CLINICAL INVESTIGATION

Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel

(2016) D Archary et al.   Mucosal Immunology

Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition

(2016) Monica Vaccari et al.   NATURE MEDICINE

The Zika Challenge

(2016) Charlotte J. Haug et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antiretroviral Therapy for the Prevention of HIV-1 Transmission

(2016) Myron S. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exploring the Potential Health Impact and Cost-Effectiveness of AIDS Vaccine within a Comprehensive HIV/AIDS Response in Low- and Middle-Income Countries

(2016) Thomas M. Harmon et al.   PLoS One

Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys

(2016) P. Abbink et al.   SCIENCE

Sustained virologic control in SIV+ macaques after antiretroviral and  4 7 antibody therapy

(2016) S. N. Byrareddy et al.   SCIENCE

HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies

(2016) Steven W. de Taeye et al.   TRENDS IN IMMUNOLOGY

Status of vaccine research and development of vaccines for dengue

(2016) Kirsten S. Vannice et al.   VACCINE

Pre-vaccination inflammation and B-cell signalling predict age-related hyporesponse to hepatitis B vaccination

(2016) Slim Fourati et al.   Nature Communications

Approaches to preventative and therapeutic HIV vaccines

(2016) Glenda E Gray et al.   Current Opinion in Virology

Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization

(2016) Cecilia Rademeyer et al.   PLoS Pathogens

Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses

(2016) Matthew Zirui Tay et al.   PLoS Pathogens

Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015

(2016) Haidong Wang et al.   Lancet HIV

Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology

(2015) Amy W. Chung et al.   CELL

Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults

(2015) J. E. Ledgerwood et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Variability at the FCGR locus: characterization in Black South Africans and evidence for ethnic variation in and out of Africa

(2015) R Lassaunière et al.   GENES AND IMMUNITY

Zoster Vaccination Increases the Breadth of CD4+T Cells Responsive to Varicella Zoster Virus

(2015) Kerry J. Laing et al.   JOURNAL OF INFECTIOUS DISEASES

Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates

(2015) Xiaoying Shen et al.   JOURNAL OF VIROLOGY

Env-Specific IgA from Viremic HIV-Infected Subjects Compromises Antibody-Dependent Cellular Cytotoxicity

(2015) María Julia Ruiz et al.   JOURNAL OF VIROLOGY

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial

(2015)   LANCET

Increased levels of inflammatory cytokines in the female reproductive tract are associated with altered expression of proteases, mucosal barrier proteins and an influx of HIV-susceptible target cells

(2015) Kelly B Arnold et al.   Mucosal Immunology

COMPASS identifies T-cell subsets correlated with clinical outcomes

(2015) Lin Lin et al.   NATURE BIOTECHNOLOGY

Bottlenecks in HIV-1 transmission: insights from the study of founder viruses

(2015) Sarah B. Joseph et al.   NATURE REVIEWS MICROBIOLOGY

Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies

(2015) W. B. Williams et al.   SCIENCE

Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys

(2015) D. H. Barouch et al.   SCIENCE

HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition

(2015) Heather A. Prentice et al.   Science Translational Medicine

Nonneutralizing Functional Antibodies: a New “Old” Paradigm for HIV Vaccines

(2014) Jean-Louis Excler et al.   Clinical and Vaccine Immunology

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial

(2014) Shuying S. Li et al.   JOURNAL OF CLINICAL INVESTIGATION

Immune activation alters cellular and humoral responses to yellow fever 17D vaccine

(2014) Enoch Muyanja et al.   JOURNAL OF CLINICAL INVESTIGATION

Fold Rise in Antibody Titers by Measured by Glycoprotein-Based Enzyme-Linked Immunosorbent Assay Is an Excellent Correlate of Protection for a Herpes Zoster Vaccine, Demonstrated via the Vaccine Efficacy Curve

(2014) Peter B. Gilbert et al.   JOURNAL OF INFECTIOUS DISEASES

Capacity for Infectious HIV-1 Virion Capture Differs by Envelope Antibody Specificity

(2014) P. Liu et al.   JOURNAL OF VIROLOGY

Impact of Clade, Geography, and Age of the Epidemic on HIV-1 Neutralization by Antibodies

(2014) P. Hraber et al.   JOURNAL OF VIROLOGY

HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities

(2014) Justin Pollara et al.   JOURNAL OF VIROLOGY

Analysis of HLA A*02 Association with Vaccine Efficacy in the RV144 HIV-1 Vaccine Trial

(2014) A. J. Gartland et al.   JOURNAL OF VIROLOGY

Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study

(2014) Glenda E Gray et al.   LANCET INFECTIOUS DISEASES

Targeting α4β7 integrin reduces mucosal transmission of simian immunodeficiency virus and protects gut-associated lymphoid tissue from infection

(2014) Siddappa N Byrareddy et al.   NATURE MEDICINE

Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection

(2014) Susan Zolla-Pazner et al.   PLoS One

Antibody persistence and T-cell balance: Two key factors confronting HIV vaccine development

(2014) G. K. Lewis et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Aggregate complexes of HIV-1 induced by multimeric antibodies

(2014) Daniel J Stieh et al.   Retrovirology

Immune Activation with HIV Vaccines

(2014) A. S. Fauci et al.   SCIENCE

Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines

(2014) A. W. Chung et al.   Science Translational Medicine

Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination

(2014) N. L. Yates et al.   Science Translational Medicine

Efficacy and Safety of the RTS,S/AS01 Malaria Vaccine during 18 Months after Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African Sites

(2014)   PLOS MEDICINE

Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses

(2014) Susan Zolla-Pazner et al.   EBioMedicine

Low Multiplicity of HIV-1 Infection and No Vaccine Enhancement in VAX003 Injection Drug Users

(2014) Sarah Sterrett et al.   Open Forum Infectious Diseases

Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals

(2013) Pamela M. Murnane et al.   AIDS

Anti-HIV IgA isotypes

(2013) Jennifer D. Watkins et al.   AIDS

Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys

(2013) Dan H. Barouch et al.   CELL

Complex Correlates of Protection After Vaccination

(2013) S. A. Plotkin   CLINICAL INFECTIOUS DISEASES

Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2

(2013) Hua-Xin Liao et al.   IMMUNITY

Vaccine-Induced Gag-Specific T Cells Are Associated With Reduced Viremia After HIV-1 Infection

(2013) Holly Janes et al.   JOURNAL OF INFECTIOUS DISEASES

Infectious Virion Capture by HIV-1 gp120-Specific IgG from RV144 Vaccinees

(2013) P. Liu et al.   JOURNAL OF VIROLOGY

High levels of IgG3 anti ICB2-5 in Plasmodium vivax-infected individuals who did not develop symptoms

(2013) Fernanda G Versiani et al.   MALARIA JOURNAL

Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine

(2013) Scott M. Hammer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial

(2013) Susan Zolla-Pazner et al.   PLoS One

Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial

(2013) Raphael Gottardo et al.   PLoS One

Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG

(2013) G. D. Tomaras et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cytomegalovirus Vectors Violate CD8+ T Cell Epitope Recognition Paradigms

(2013) S. G. Hansen et al.   SCIENCE

Does participation in an HIV vaccine efficacy trial affect risk behaviour in South Africa?

(2013) G.E. Gray et al.   VACCINE

The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120

(2012) Nicos Karasavvas et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Association of Fc  receptor IIIa genotype with the rate of HIV infection after gp120 vaccination

(2012) D. N. Forthal et al.   BLOOD

Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model

(2012) Laurent Coudeville et al.   BMC Medical Research Methodology

Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50-59 Years

(2012) K. E. Schmader et al.   CLINICAL INFECTIOUS DISEASES

Nomenclature for Immune Correlates of Protection After Vaccination

(2012) S. A. Plotkin et al.   CLINICAL INFECTIOUS DISEASES

Extended Follow-up Confirms Early Vaccine-Enhanced Risk of HIV Acquisition and Demonstrates Waning Effect Over Time Among Participants in a Randomized Trial of Recombinant Adenovirus HIV Vaccine (Step Study)

(2012) A. Duerr et al.   JOURNAL OF INFECTIOUS DISEASES

Early Appearance of Neutralizing Immunoglobulin G3 Antibodies Is Associated With Chikungunya Virus Clearance and Long-term Clinical Protection

(2012) Yiu-Wing Kam et al.   JOURNAL OF INFECTIOUS DISEASES

Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family

(2012) M. Bonsignori et al.   JOURNAL OF VIROLOGY

Antigenicity and Immunogenicity of RV144 Vaccine AIDSVAX Clade E Envelope Immunogen Is Enhanced by a gp120 N-Terminal Deletion

(2012) S. Munir Alam et al.   JOURNAL OF VIROLOGY

Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144

(2012) Merlin L Robb et al.   LANCET INFECTIOUS DISEASES

Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2

(2012) Morgane Rolland et al.   NATURE

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

(2012) Barton F. Haynes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preexposure Prophylaxis for HIV Infection among African Women

(2012) Lut Van Damme et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

Merck Ad5/HIV induces broad innate immune activation that predicts CD8+ T-cell responses but is attenuated by preexisting Ad5 immunity

(2012) D. E. Zak et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immune markers and correlates of protection for vaccine induced immune responses

(2012) Aneesh Thakur et al.   VACCINE

Transmitted/Founder and Chronic Subtype C HIV-1 Use CD4 and CCR5 Receptors with Equal Efficiency and Are Not Inhibited by Blocking the Integrin α4β7

(2012) Nicholas F. Parrish et al.   PLoS Pathogens

Prediction of Pneumococcal Conjugate Vaccine Effectiveness against Invasive Pneumococcal Disease Using Opsonophagocytic Activity and Antibody Concentrations Determined by Enzyme-Linked Immunosorbent Assay with 22F Adsorption

(2011) L. Schuerman et al.   Clinical and Vaccine Immunology

An Ad5-Vectored HIV-1 Vaccine Elicits Cell-mediated Immunity but does not Affect Disease Progression in HIV-1–infected Male Subjects: Results From a Randomized Placebo-Controlled Trial (The Step Study)

(2011) D. W. Fitzgerald et al.   JOURNAL OF INFECTIOUS DISEASES

An HIV-1 gp120 Envelope Human Monoclonal Antibody That Recognizes a C1 Conformational Epitope Mediates Potent Antibody-Dependent Cellular Cytotoxicity (ADCC) Activity and Defines a Common ADCC Epitope in Human HIV-1 Serum

(2011) G. Ferrari et al.   JOURNAL OF VIROLOGY

Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study

(2011) Glenda E Gray et al.   LANCET INFECTIOUS DISEASES

CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates

(2011) Nancy J Sullivan et al.   NATURE MEDICINE

Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial

(2011) Morgane Rolland et al.   NATURE MEDICINE

First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Prevention of HIV-1 Infection with Early Antiretroviral Therapy

(2011) Myron S. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hemagglutination Inhibition Antibody Titers as a Correlate of Protection for Inactivated Influenza Vaccines in Children

(2011) Steven Black et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Trivalent Adenovirus Type 5 HIV Recombinant Vaccine Primes for Modest Cytotoxic Capacity That Is Greatest in Humans with Protective HLA Class I Alleles

(2011) Stephen A. Migueles et al.   PLoS Pathogens

Correlates of Protection Induced by Vaccination

(2010) S. A. Plotkin   Clinical and Vaccine Immunology

Induction of Immunity to Human Immunodeficiency Virus Type-1 by Vaccination

(2010) M. Juliana McElrath et al.   IMMUNITY

Magnitude and Breadth of a Nonprotective Neutralizing Antibody Response in an Efficacy Trial of a Candidate HIV‐1 gp120 Vaccine

(2010) Peter Gilbert et al.   JOURNAL OF INFECTIOUS DISEASES

Phenotypic and Functional Profile of HIV-Inhibitory CD8 T Cells Elicited by Natural Infection and Heterologous Prime/Boost Vaccination

(2010) S. A. Freel et al.   JOURNAL OF VIROLOGY

Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men

(2010) Robert M. Grant et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women

(2010) Q. Abdool Karim et al.   SCIENCE

Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms

(2010) Devon J. Shedlock et al.   VIROLOGY

Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine

(2010) Glenda Gray et al.   Current Opinion in HIV and AIDS

Host Genetics and HIV-1: The Final Phase?

(2010) Jacques Fellay et al.   PLoS Pathogens

High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men

(2010) Hui Li et al.   PLoS Pathogens

Varicella‐Zoster Virus–Specific Immune Responses to Herpes Zoster in Elderly Participants in a Trial of a Clinically Effective Zoster Vaccine

(2009) Adriana Weinberg et al.   JOURNAL OF INFECTIOUS DISEASES

Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule

(2009) Nancy J. Sullivan et al.   NATURE REVIEWS MICROBIOLOGY

Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand

(2009) Supachai Rerks-Ngarm et al.   NEW ENGLAND JOURNAL OF MEDICINE

The integrin  4 7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1

(2009) C. Cicala et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Vaccines: Correlates of Vaccine‐Induced Immunity

(2008) Stanley A. Plotkin   CLINICAL INFECTIOUS DISEASES

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis

(2008) M Juliana McElrath et al.   LANCET

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

(2008) Susan P Buchbinder et al.   LANCET

HIV-1 envelope protein binds to and signals through integrin α4β7, the gut mucosal homing receptor for peripheral T cells

(2008) James Arthos et al.   NATURE IMMUNOLOGY

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection

(2008) B. F. Keele et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine

(2008) Elmar A. Joura et al.   VACCINE